Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(USE-0961) The human immune response to Staphylococcus aureus

 Return to List of Clinical Studies
 Return to List of Protocols for Immunology
The human immune response to Staphylococcus aureus

Principal Investigator:
Uri Sela MD, PhD


Contact Information:
Clinical Rsearch Support Office
1230 York Avenue
New York, NY 10065
Telephone: 1.800.RUCARES
Enrollment Status:
Open to Enrollment

Brief Summary of Protocol:
economic burden on today’s health care system. Infections with SA that are resistant to Methicillin antibiotic (MRSA) are very common and are a major part of this burden. 30% of the population are colonized with S. aureus, so at least theoretically their immune system is constantly exposed to the bacteria, and expected to induce protective immunity. However, at the same time, 30% of the population experiencing an infection with S. aureus will be afflicted with recurrent infections with this bacterium, and despite previous exposure.
Developing a vaccine would be an ideal solution for prevention of these infections. However, despite intensive study in the last 3 decades, a successful vaccine against S.aureus is still unavailable. For developing and designing an efficient vaccine, a better understanding of the immune response to S. aureus is needed..For many yearsthe concept was that B cell responses and antibody production are enough for protection against S.aureus. In recent years, direct evidence from KO mice as well as evidence from humans with primary immune deficiency demonstrates that CD4 Th1 and Th17 immune responses are necessary for protection from S. aureus. Nevertheless, our recent results demonstrate that the Th1 and Th17 response to the various S. aureus strains varied extensively in response to in-vitro stimulation. Further, wide variability was also inspected in IgG expression by proliferating B cells in response to the different strains. We could show that mobile genetic elements carried by phages are responsible for a significant portion of this immune response variability. These findings are bringing up the possibility that the strain specificity is a new factor that might need to be taken into account when we are evaluating protection. At this time point, what is not known/understood, and what we want to clarify in the current study is:
(i) Whether previous exposure to various strains results in different level of protective memory. (ii) How immune memory induced by exposure to one strain affect the ability to respond to other strains of S. aureus.

Detailed Description of Protocol:

What specifically makes a person eligible for the study?
You may be eligible to enter this study:

- Are eligible between 18 and 60
- Do not have HIV
- Do not have Hepatitis B or C



Children permitted to participate:

Potential Benefits.....

Compensation is provided.